Nafamostat Mesylate for Sepsis-Related Blood Clotting Problems
Treatments studied
Part of Blood & lymphatic, Infections clinical trials.
This trial tests if a drug called nafamostat mesylate can help people with sepsis who have blood clotting problems and need a special type of kidney treatment (hemofiltration). It may improve their chances of recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a condition called sepsis-induced coagulopathy (blood clotting problems caused by sepsis).
- You must be receiving a blood-filtering treatment called hemofiltration.
- You cannot be pregnant, breastfeeding, or have a known allergy to nafamostat mesylate.
- You must not have a very low level of a clotting protein called fibrinogen (below 1.5 g/L).
- You must not have active bleeding or a high risk of bleeding, including recent head injury, bleeding disorders, or severe liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called nafamostat mesilate to help control blood clotting problems caused by severe infections (sepsis). It may be an option for people with sepsis who are at risk of bleeding but do not have active bleeding.
This trial tests two different blood-thinning methods used during continuous kidney-support treatment (CRRT) for patients who have developed severe kidney injury due to sepsis. The goal is to see which method works better and is safer for patients in this critical condition.
This trial tests two blood thinners (nafamostat and heparin) during kidney dialysis for people with sepsis-related acute kidney injury. The goal is to find which is safer and works better.
This trial is testing different doses of a blood thinner called nafamostat in patients who are in the ICU and need continuous kidney dialysis (CRRT). The goal is to find which dose works best to prevent clots in the dialysis machine without causing bleeding problems.
This trial tests a medicine called nafamostat mesilate to prevent blood clots in patients who need ECMO (a machine that helps your heart and lungs) after heart surgery. It may offer a safer way to thin the blood compared to standard treatments.
This pilot study tests whether nafamostat is safe for people on hemodialysis who have a high risk of bleeding. It may help clinicians find safer ways to manage blood clotting medicines during dialysis.
Hear when a new Sepsis-induced Coagulopathy (SIC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.